| Name | Title | Contact Details |
|---|---|---|
Shalom Shushan |
Chief Technology Officer | Profile |
Liberty Drug and Surgical is a Chatham, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Founded in 2007, Surgical Solutions, LLC is a national company headquartered in Chicago and Henderson, Kentucky (part of the Evansville, Indiana metropolitan area). The company specializes in providing non-clinical surgical services for minimally invasive (endoscopic and laparoscopic) surgical procedures to hospitals throughout the US.
At Vicarious Surgical we are revolutionizing the field of surgical robotics. We seek to improve the lives of patients, enhance the ability of surgeons, and expand worldwide access to high-quality care through the use of surgical robotics. We have reimagined what is possible by building a human-like surgical robot and combining it with the world`s first virtual-reality surgical camera to allow surgeons to perform minimally-invasive surgery with the ease of an open procedure.
Ultradent Products, Inc., is a leading developer of high-tech dental materials, devices, and instruments worldwide. Ultradent`s mission is to improve the level of dental health care and to make dental procedures more predictable and efficient. Consistent with its mission, Ultradent works to improve the quality of life and the health of individuals through financial and charitable programs.
Motif Neurotech is a clinical-stage company leading the development of minimally invasive neuromodulation therapeutics for mental health. The company`s lead product, for treatment resistant depression (TRD), is a miniature implant that is designed to treat TRD by increasing activity in the prefrontal cortex. Studies over 20 years show stimulation of the pre-frontal cortex effectively treats treatment resistant depression without the side effects of anti-depressants. However, existing brain stimulation treatments like transcranial magnetic stimulation (TMS) can be expensive and challenging for patients to access, with daily treatments required for six weeks that may need to be repeated. Human and large animal studies show Motif`s prototype stimulates target brain areas like TMS, and the company is preparing to begin clinical trials of their first chronic implants in 2025. Motif`s implant is enabled by patent-pending wireless magnetoelectric power transfer developed at Rice University. Motif`s founders and key team members are clinical, medical device and academic experts with over 5,000 surgical procedures and decades of medical device experience.